CVE-2026-52866
Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT Missing Authorization
An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.
Attack profile
How easy it is to exploit
- Attack vector
- Adjacent network
- Complexity
- Low
- Privileges needed
- None
- User interaction
- None
What an attacker can affect
- Confidentiality
- None
- Integrity
- None
- Availability
- High
Exploit likelihood
What each source reports
CVE List Score used
Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT Missing Authorization
An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.
- Record
CVE-2026-52866- CVSS 4.0
- 7.1 High
CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N - CVSS 3.1
- 6.5 Medium
CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H - Weakness
- CWE-862
- Updated
- 2026-11-02
EUVDEUVD-2026-37970
An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.
- Record
EUVD-2026-37970- CVSS 4.0
- 7.1 High
CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N - Updated
- 2026-11-02
GitHub AdvisoriesGHSA-47r7-422p-6w2p
An attacker within BLE communication range can monopolize the device's only available BLE...
An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.
- Record
GHSA-47r7-422p-6w2p- CVSS 4.0
- 7.1 High
CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X - CVSS 3.1
- 6.5 Medium
CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H - Weakness
- CWE-862
- Updated
- 2026-11-02
NVD
An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.
- Record
CVE-2026-52866- CVSS 4.0
- 7.1 High
CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X - CVSS 3.1
- 6.5 Medium
CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H - Weakness
- CWE-862
- Updated
- 2026-11-02
Affected products
History
| Recorded | Changed | Sources |
|---|---|---|
| first indexed | CVE List, EUVD, GitHub Advisories, NVD |
Dates are when Every CVE recorded each change. Upstream dates may differ.
In short
CVE-2026-52866 is a high vulnerability (CVSS 7.1) in Apollo Pharmacy Blood Glucose Monitoring System (model No. Apg-01 Bt), published June 18, 2026. No source lists public exploit code. EPSS puts the chance of exploitation in the next 30 days at 0.35%, the 28th percentile. No source names a fixed version.
References
apollopharmacy.in/contact-us
cisa.gov/news-events/news/understanding-bluetooth-technology
github.com/cisagov/CSAF/blob/develop/csaf_files/OT/white/2026/icsma-26-169-01.json
nvd.nist.gov/vuln/detail/CVE-2026-52866